Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development PDF full book. Access full book title Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development by Andrew J. Krentz. Download full books in PDF and EPUB format.
Author: Andrew J. Krentz Publisher: Springer ISBN: 1447149203 Category : Medical Languages : en Pages : 316
Book Description
The world is beset by a pandemic of obesity and type 2 diabetes and the need for new drugs is startlingly clear; recent years have seen a huge increase in research activity to fill this gap. The development of new drugs for diabetes and obesity must be founded upon a sound appreciation of the pathophysiology of these common disorders. The dual defects of insulin resistance and impaired insulin secretion are fundamental to the pathogenesis and progression of obesity-associated type 2 diabetes. There is a need to explain how new drugs can counter insulin resistance and insulin deficiency to a broad range of professionals, from clinical scientists active in early (and later) phase drug development to specialist physicians and increasingly primary care doctors who must tailor drug regimens to the individual patient. Clinical research methods for measuring insulin action and insulin secretion have become well-established in proof-of-mechanism studies; however, selection of the best techniques is by no means straightforward. The purpose of the book is to aid the selection of the most appropriate techniques for assessing insulin action, insulin secretion and body composition in humans (with particular reference to new drugs) in phase 1 and 2 studies and aid the understanding of drug effects and non-drug treatment strategies on key biochemical-hormonal defects of obesity and type 2 diabetes. The book will assume a working knowledge of human physiology relating to glucose metabolism and will be of interest to biomedical scientists, pharmacologists, academics involved in metabolic research and clinicians practicing in these specialties.
Author: Andrew J. Krentz Publisher: Springer ISBN: 1447149203 Category : Medical Languages : en Pages : 316
Book Description
The world is beset by a pandemic of obesity and type 2 diabetes and the need for new drugs is startlingly clear; recent years have seen a huge increase in research activity to fill this gap. The development of new drugs for diabetes and obesity must be founded upon a sound appreciation of the pathophysiology of these common disorders. The dual defects of insulin resistance and impaired insulin secretion are fundamental to the pathogenesis and progression of obesity-associated type 2 diabetes. There is a need to explain how new drugs can counter insulin resistance and insulin deficiency to a broad range of professionals, from clinical scientists active in early (and later) phase drug development to specialist physicians and increasingly primary care doctors who must tailor drug regimens to the individual patient. Clinical research methods for measuring insulin action and insulin secretion have become well-established in proof-of-mechanism studies; however, selection of the best techniques is by no means straightforward. The purpose of the book is to aid the selection of the most appropriate techniques for assessing insulin action, insulin secretion and body composition in humans (with particular reference to new drugs) in phase 1 and 2 studies and aid the understanding of drug effects and non-drug treatment strategies on key biochemical-hormonal defects of obesity and type 2 diabetes. The book will assume a working knowledge of human physiology relating to glucose metabolism and will be of interest to biomedical scientists, pharmacologists, academics involved in metabolic research and clinicians practicing in these specialties.
Author: Andrew J. Krentz Publisher: Springer ISBN: 3030117480 Category : Medical Languages : en Pages : 557
Book Description
This book aims to aid the selection of the most appropriate methods for use in early phase (1 and 2) clinical studies of new drugs for diabetes, obesity, non-alcoholic fatty liver disease (NAFLD) and related cardiometabolic disorders. Clinical research methods to assess the pharmacokinetics and pharmacodynamics of new diabetes drugs, e.g. the euglycemic clamp technique, have become well-established in proof-of-mechanism studies. However, selection of the most appropriate techniques is by no means straightforward. Moreover, the application of such methods must conform to the regulatory requirements for new drugs. This book discusses the need for new pharmacotherapies for diabetes, obesity and NAFLD and the molecular targets of drugs currently in development. Emerging technologies including functional imaging, circulating biomarkers and omics are considered together with practical and ethical issues pertaining to early phase clinical trials in subjects with cardiometabolic disorders. Translational Research Methods in Diabetes, Obesity, and Non-Alcoholic Fatty Liver Disease is of interest to biomedical scientists, pharmacologists, academics involved in metabolic research and clinicians practicing in these specialties.
Author: Gundu H. R. Rao Publisher: Elsevier ISBN: 0323954715 Category : Science Languages : en Pages : 566
Book Description
Cardiometabolic diseases are a group of metabolic dysfunctions mainly characterized by insulin resistance, impaired glucose tolerance, dyslipidemia, hypertension, and central adiposity that are major contributors to increased risk of acute vascular events such as myocardial infarction, heart failure and stroke. Cardiometabolic Diseases: Molecular Basis, Early Detection of Risks, and Management provides detailed information on all aspects of metabolic dysfunctions and associated risks for cardiometabolic diseases, including a thoughtful discussion of cellular and molecular mechanisms involved in the progression of metabolic risks, the approaches for the early detection and robust management of metabolic risks. Written by a team of expert contributors, this book is useful reading for researchers and clinicians interested on recent advances in etiology of cardiometabolic diseases, the latest noninvasive approaches for diagnosis, risk assessment tools, therapeutic strategies, and also aspects of prevention of cardiometabolic diseases. - Covers all aspects of cardiometabolic diseases, from cellular and molecular mechanisms involved in the development of metabolic risks to clinical practice - Provides established guidelines that facilitate effective management of the independent risk factors that promote vascular diseases - Discusses the use of diagnostic tools to empower patients to self-monitor the progress or regress of modifiable risks
Author: Empar Lurbe Publisher: Springer ISBN: 3030181677 Category : Medical Languages : en Pages : 281
Book Description
This book is devoted to hypertension in children and adolescents, a clinical issue that – thanks to the strides made in several areas of pathophysiological and clinical research – has received growing interest in cardiovascular medicine over the last several years. Given the increasing prevalence of hypertension in children and adolescents, this book represents an important and useful tool to address what has become a significant public health issue. It covers a diverse range of topics, from advances in the definition of hypertension and the identification of new risk factors, to current treatment strategies. The book also presents an overview of the latest findings, including the clinical significance of isolated systolic hypertension (ISH) in youth, the importance of out-of-office and central blood pressure measurement, new methods for assessing vascular phenotypes, and clustering of CV risk factors. Gathering contributions by international experts and pursuing a practice-oriented approach, the book offers a valuable tool for cardiologists, pediatricians and nephrologists, as well as general practitioners.
Author: Dorairaj Prabhakaran Publisher: World Bank Publications ISBN: 1464805202 Category : Medical Languages : en Pages : 948
Book Description
Cardiovascular, respiratory, and related conditions cause more than 40 percent of all deaths globally, and their substantial burden is rising, particularly in low- and middle-income countries (LMICs). Their burden extends well beyond health effects to include significant economic and societal consequences. Most of these conditions are related, share risk factors, and have common control measures at the clinical, population, and policy levels. Lives can be extended and improved when these diseases are prevented, detected, and managed. This volume summarizes current knowledge and presents evidence-based interventions that are effective, cost-effective, and scalable in LMICs.
Author: Claudio Carini Publisher: CRC Press ISBN: 0429574622 Category : Mathematics Languages : en Pages : 953
Book Description
"The field of Biomarkers and Precision Medicine in drug development is rapidly evolving and this book presents a snapshot of exciting new approaches. By presenting a wide range of biomarker applications, discussed by knowledgeable and experienced scientists, readers will develop an appreciation of the scope and breadth of biomarker knowledge and find examples that will help them in their own work." -Maria Freire, Foundation for the National Institutes of Health Handbook of Biomarkers and Precision Medicine provides comprehensive insights into biomarker discovery and development which has driven the new era of Precision Medicine. A wide variety of renowned experts from government, academia, teaching hospitals, biotechnology and pharmaceutical companies share best practices, examples and exciting new developments. The handbook aims to provide in-depth knowledge to research scientists, students and decision makers engaged in Biomarker and Precision Medicine-centric drug development. Features: Detailed insights into biomarker discovery, validation and diagnostic development with implementation strategies Lessons-learned from successful Precision Medicine case studies A variety of exciting and emerging biomarker technologies The next frontiers and future challenges of biomarkers in Precision Medicine Claudio Carini, Mark Fidock and Alain van Gool are internationally recognized as scientific leaders in Biomarkers and Precision Medicine. They have worked for decades in academia and pharmaceutical industry in EU, USA and Asia. Currently, Dr. Carini is Honorary Faculty at Kings’s College School of Medicine, London, UK. Dr. Fidock is Vice President of Precision Medicine Laboratories at AstraZeneca, Cambridge, UK. Prof.dr. van Gool is Head Translational Metabolic Laboratory at Radboud university medical school, Nijmegen, NL.
Author: Bruce H. Littman Publisher: Cambridge University Press ISBN: 113949872X Category : Medical Languages : en Pages : 385
Book Description
This book focuses on the new discipline of translational medicine as it pertains to drug development within the pharmaceutical and biotechnology industry. It is essential for anyone interested in translational medicine from a variety of backgrounds: university institutes, medical schools, pharmaceutical companies and drug development researchers and decision-makers.
Author: Institute of Medicine Publisher: National Academies Press ISBN: 0309284740 Category : Medical Languages : en Pages : 179
Book Description
In 2006 the National Institutes of Health (NIH) established the Clinical and Translational Science Awards (CTSA) Program, recognizing the need for a new impetus to encourage clinical and translational research. At the time it was very difficult to translate basic and clinical research into clinical and community practice; making it difficult for individual patients and communities to receive its benefits. Since its creation the CTSA Program has expanded, with 61 sites spread across the nation's academic health centers and other institutions, hoping to provide catalysts and test beds for policies and practices that can benefit clinical and translation research organizations throughout the country. The NIH contracted with the Institute of Medicine (IOM) in 2012 to conduct a study to assess and provide recommendations on appropriateness of the CTSA Program's mission and strategic goals and whether changes were needed. The study was also address the implementation of the program by the National Center for Advancing Translational Sciences (NCATS) while exploring the CTSA's contributions in the acceleration of the development of new therapeutics. A 13-member committee was established to head this task; the committee had collective expertise in community outreach and engagement, public health and health policy, bioethics, education and training, pharmaceutical research and development, program evaluation, clinical and biomedical research, and child health research. The CTSA Program at NIH: Opportunities for Advancing Clinical and Translational Research is the result of investigations into previous program evaluations and assessments, open-session meetings and conference class, and the review of scientific literature. Overall, the committee believes that the CTSA Program is significant to the advancement of clinical and translational research through its contributions. The Program would benefit from a variety of revisions, however, to make it more efficient and effective.
Author: Andrew J. Krentz
Author: Andrew J. Krentz
Author: Andrew J. Krentz
Author: Gundu H. R. Rao
Author: National Academies of Sciences Engineering and Medicine
Author: Magdalene K. Montgomery
Author: Empar Lurbe
Author: Dorairaj Prabhakaran
Author: Claudio Carini
Author: Bruce H. Littman
Author: Institute of Medicine